Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Peijia Medical Technology (Suzhou) Co., Ltd.

Clinicaltrial registered2 Nov 2026

Peijia Medical Technology (Suzhou) Co., Ltd.

2 Nov 2026: Trial registered · Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
2 Nov 2026
Title
Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis
Conditions
Aortic Stenosis
Phase
Not applicable
Study Type
Interventional
Status
Active Not Recruiting
Countries
China
Country
China
Reference
NCT07908225
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Peijia Medical Technology (Suzhou) Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.